Indian drugmakers posted 21% month-on-month growth in November sales, which was the highest in the past 14 months, driven by an increase in demand for respiratory anti-infective drugs.
According to data from research body All India Organisation of Chemists and Druggists (AIOCD), domestic drugmakers posted sales of Rs 4,912 crore in November compared with Rs 4,668 crore in October. "This is indicative of flare-up in viral and bacterial infections," said Ameesh Masurekar, director, AIOCD.
However, he sees revenue growth falling to 14-15% once the seasonal demand for viral and bacterial infection drugs comes down. Analysts said the November numbers should improve pharma companies' revenues for the October-December quarter at a time when most drugmakers are expected to post mark-to-market loss due to rupee depreciation.
The top 20 drug companies registered a double-digit growth, AIOCD data showed. McLeod's Pharma, which has been growing consistently month-on-month, recorded the highest growth in sales.
Analysts see the drugmaker surpassing Dr Reddy's in total sales within four-five months. "The anti-infective segment seems to have bounced back, as the last couple of months this segment was dragging down sales," said Ranjit Kapadia, vice president, Centrum Capital.
According to data from research body All India Organisation of Chemists and Druggists (AIOCD), domestic drugmakers posted sales of Rs 4,912 crore in November compared with Rs 4,668 crore in October. "This is indicative of flare-up in viral and bacterial infections," said Ameesh Masurekar, director, AIOCD.
However, he sees revenue growth falling to 14-15% once the seasonal demand for viral and bacterial infection drugs comes down. Analysts said the November numbers should improve pharma companies' revenues for the October-December quarter at a time when most drugmakers are expected to post mark-to-market loss due to rupee depreciation.
The top 20 drug companies registered a double-digit growth, AIOCD data showed. McLeod's Pharma, which has been growing consistently month-on-month, recorded the highest growth in sales.
Analysts see the drugmaker surpassing Dr Reddy's in total sales within four-five months. "The anti-infective segment seems to have bounced back, as the last couple of months this segment was dragging down sales," said Ranjit Kapadia, vice president, Centrum Capital.
No comments:
Post a Comment